Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma

Leo Rasche • 28 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Talquetamab

In this video, Leo Rasche, MD, University of Würzburg, Würzburg, Germany, discusses a recent study in which whole-genome sequencing (WGS) data demonstrated a loss of BCMA and GPRC5D in patients with relapsed/refractory (R/R) multiple myeloma treated with bispecific antibodies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Leo Rasche

2:18
Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patients
Leo Rasche • 28 Sep 2023
1:02
Promising novel targets emerging in myeloma & the value of combining agents
Leo Rasche • 28 Sep 2023
9:00
Genomics in the age of I-O
Francesco Maura et al. • 26 Mar 2022
1:06
CAR-NK: improved CRS and promising safety profiles in myeloma
Leo Rasche • 14 Jun 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals